CL2016001081A1 - Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática - Google Patents

Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática

Info

Publication number
CL2016001081A1
CL2016001081A1 CL2016001081A CL2016001081A CL2016001081A1 CL 2016001081 A1 CL2016001081 A1 CL 2016001081A1 CL 2016001081 A CL2016001081 A CL 2016001081A CL 2016001081 A CL2016001081 A CL 2016001081A CL 2016001081 A1 CL2016001081 A1 CL 2016001081A1
Authority
CL
Chile
Prior art keywords
ccl17
asthma
vector
pharmaceutical composition
host cell
Prior art date
Application number
CL2016001081A
Other languages
English (en)
Inventor
Ken Boakye
Vecchio Alfred Del
John Kehoe
Eilyn Lacy
Lynne Murray
Mary Ryan
Sandra Santulli-Marotto
John Wheeler
Brian Whitaker
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2016001081A1 publication Critical patent/CL2016001081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con un anticuerpo anti el ligando 17 de quimioquina (CCL17) humana. Así mismo, el invento reivindica una composición farmacéutica que comprende el anticuerpo anti-CCL17, el polinucleótido que lo codifica, vector y célula huésped que comprende el polinucleótido y método de producción del anticuerpo anti-CCL17. El invento también abarca el uso del anticuerpo anti-CCL17 para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática.
CL2016001081A 2013-11-06 2016-05-05 Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática CL2016001081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900596P 2013-11-06 2013-11-06

Publications (1)

Publication Number Publication Date
CL2016001081A1 true CL2016001081A1 (es) 2016-10-21

Family

ID=53007215

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001081A CL2016001081A1 (es) 2013-11-06 2016-05-05 Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática

Country Status (33)

Country Link
US (4) US9944697B2 (es)
EP (2) EP3065774B1 (es)
JP (1) JP6556742B2 (es)
KR (1) KR102331054B1 (es)
CN (1) CN105722531B (es)
AU (1) AU2014346770B2 (es)
BR (1) BR112016010071A2 (es)
CA (1) CA2929166C (es)
CL (1) CL2016001081A1 (es)
CR (1) CR20160187A (es)
CY (1) CY1124445T1 (es)
DK (1) DK3065774T3 (es)
DO (1) DOP2016000105A (es)
EA (1) EA034655B1 (es)
ES (1) ES2884255T3 (es)
HR (1) HRP20211234T1 (es)
HU (1) HUE058272T2 (es)
IL (1) IL245488B (es)
LT (1) LT3065774T (es)
MA (1) MA39090B2 (es)
MX (1) MX2016005982A (es)
MY (1) MY192757A (es)
NZ (2) NZ719506A (es)
PE (1) PE20160856A1 (es)
PH (1) PH12016500826B1 (es)
PL (1) PL3065774T3 (es)
PT (1) PT3065774T (es)
RS (1) RS62373B1 (es)
SG (1) SG11201603231XA (es)
SI (1) SI3065774T1 (es)
SM (1) SMT202100473T1 (es)
UA (1) UA119973C2 (es)
WO (1) WO2015069865A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065774B1 (en) * 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies
WO2017065203A1 (ja) * 2015-10-14 2017-04-20 日本全薬工業株式会社 イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌｔａｒｃ抗体
WO2017079369A2 (en) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
TWI899280B (zh) * 2020-07-10 2025-10-01 日商積水醫療股份有限公司 含有tarc之組成物及tarc之保存穩定性之提升方法
JP6979149B1 (ja) * 2020-07-10 2021-12-08 積水メディカル株式会社 Ｔａｒｃを含有する組成物、及びｔａｒｃの保存安定性向上方法
WO2024127277A1 (en) 2022-12-16 2024-06-20 Glaxosmithkline Intellectual Property Development Limited Method of treating pain with an anti-ccl17 antibody

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US226A (en) 1837-06-03 Samuel goss
US4683985A (en) 1985-01-04 1987-08-04 Dresser Industries, Inc. Lubrication system for a vertical gear unit
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
WO1997029192A1 (en) 1996-02-12 1997-08-14 Schering Corporation Mammalian dendritic cell chemokine reagents
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002006630A1 (en) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP4341704B2 (ja) 2007-07-12 2009-10-07 トヨタ自動車株式会社 ハイブリッド車両およびハイブリッド車両の制御方法
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2604279A1 (en) * 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
KR101603001B1 (ko) * 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
ES2757857T3 (es) 2010-09-27 2020-04-30 Janssen Biotech Inc Anticuerpos de unión a colágeno II humano
US9012602B2 (en) * 2010-09-27 2015-04-21 Janssen Biotech, Inc. Macaca fascicularis CCL17
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130171659A1 (en) * 2011-12-28 2013-07-04 Abbott Japan Co., Ltd. Methods of prognosis and diagnosis of rheumatoid arthritis
EP3065774B1 (en) * 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies

Also Published As

Publication number Publication date
PT3065774T (pt) 2021-08-31
CN105722531A (zh) 2016-06-29
BR112016010071A2 (pt) 2017-12-05
PH12016500826A1 (en) 2016-06-13
AU2014346770B2 (en) 2020-05-21
EA034655B1 (ru) 2020-03-03
CN105722531B (zh) 2020-03-06
DOP2016000105A (es) 2016-10-31
HUE058272T2 (hu) 2022-07-28
MA39090A1 (fr) 2018-03-30
NZ758354A (en) 2022-09-30
JP2016537024A (ja) 2016-12-01
KR20160077198A (ko) 2016-07-01
US20220348647A1 (en) 2022-11-03
IL245488A0 (en) 2016-06-30
KR102331054B1 (ko) 2021-11-24
WO2015069865A1 (en) 2015-05-14
SMT202100473T1 (it) 2021-09-14
EP3065774A1 (en) 2016-09-14
MA39090B2 (fr) 2021-10-29
HRP20211234T1 (hr) 2021-11-26
MX2016005982A (es) 2016-08-11
PL3065774T3 (pl) 2021-12-13
UA119973C2 (uk) 2019-09-10
US20210017267A1 (en) 2021-01-21
US20150125458A1 (en) 2015-05-07
US9944697B2 (en) 2018-04-17
DK3065774T3 (da) 2021-08-23
LT3065774T (lt) 2021-09-10
EA201690942A1 (ru) 2016-09-30
PE20160856A1 (es) 2016-09-03
CR20160187A (es) 2016-08-04
RS62373B1 (sr) 2021-10-29
NZ719506A (en) 2022-09-30
CA2929166C (en) 2023-08-22
SI3065774T1 (sl) 2021-11-30
US10829549B2 (en) 2020-11-10
MY192757A (en) 2022-09-07
SG11201603231XA (en) 2016-05-30
CY1124445T1 (el) 2022-07-22
EP3065774B1 (en) 2021-05-26
CA2929166A1 (en) 2015-05-14
EP3065774A4 (en) 2017-06-21
US20180171007A1 (en) 2018-06-21
PH12016500826B1 (en) 2021-09-10
EP3466445A1 (en) 2019-04-10
JP6556742B2 (ja) 2019-08-07
ES2884255T3 (es) 2021-12-10
IL245488B (en) 2020-03-31
US11414484B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
CL2016001081A1 (es) Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
MX2020010841A (es) Composicion detergente.
IL259147A (en) Exosomes derived from mesenchymal stem cells and their uses
EP4324919A3 (en) Polypeptide variants
WO2017060493A9 (en) Polypeptides
MX370643B (es) Poligalactomanano sustituido con dihidroxialquilo, y métodos para producir y utilizar el mismo.
MY185817A (en) Methods for production of oxygenated terpenes
CL2017000703A1 (es) Anticuerpos anti-il-25 y usos de los mismos
MX2021008341A (es) Gen con resistencia a roya.
PH12015502117A1 (en) High cleaning silica with low abrasion and method for making same
MX395060B (es) Sistemas y métodos de control adecuados para el uso con sistemas y métodos de producción de energía.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
PL2970052T3 (pl) Sposób wytwarzania 2-chloro-1,1,1,2-tetrafluoropropanu (HCFC-244bb)
SG11201802596XA (en) Clostridium beijerinckii, use thereof, and method of producing butanol
MY183061A (en) Polypeptides having xylanase activity with a high conversion rate of xylose-containing polysaccharides
MX2021006458A (es) Pared celular de levadura enriquecida en proteina de manano-oligosacarido.
MX362070B (es) Polioles que contienen tanino, su producción y su uso.
ZA201706794B (en) Methods and compositions to inhibit symptoms associated with veisalgia
ZA201804457B (en) Process to reduce the overall energy consumption in the production of nanocellulose
SI3122695T1 (sl) Fotokatalitska sestava na osnovi cementa in njena uporaba za pridobivanje vodnih barv, zlasti za zunanjo uporabo
MX2015016603A (es) Composiciones de corticosteroides.
CL2017002224A1 (es) Composiciones para mejorar la brotación y la floración
ZA201704635B (en) Novel acetals of 1-(3,3-dimethylcyclohex-1-enyl) ethanone, method for the production thereof and use of same in perfumery
MX383014B (es) Formulaciones de antibióticos tópicas..